AlexanderMLesokhinMD

PubMed

• Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies.
  Anna J Howard, Isabel Concepcion, Alice X Wang, Issam S Hamadeh, Malin L Hultcrantz, Sham Mailankody, Carlyn Rose Tan, Neha Korde, Alexander M Lesokhin, Hani Hassoun, ...> ;Blood Advances. 2024 Apr 12
• Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy.
  Issam S Hamadeh, Tala Shekarkhand, Colin Joseph Rueda, Ross S Firestone, Alice X Wang, Neha Korde, Malin L Hultcrantz, Alexander M Lesokhin, Sham Mailankody, Hani Hass...> ;Blood Advances. 2024 Apr 10
• 1 citations
  CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
  Ross S Firestone, Devin McAvoy, Tala Shekarkhand, Edith Serrano, Issam Hamadeh, Alice Wang, Menglei Zhu, Wei Ge Qin, Dhwani Patel, Carlyn R Tan, Malin Hultcrantz, Sham...> ;Blood Advances. 2024 Apr 9
• Soluble B-cell maturation antigen in multiple myeloma.
  Bruno Almeida Costa, Ricardo J Ortiz, Alexander M Lesokhin, Joshua Richter> ;American Journal of Hematology. 2024 Apr 1
• Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma.
  Lesokhin, A., Nath, K., Shekarkhand, T., Nemirovsky, D., Derkach, A., Costa, B., Nishimura, N., Farzana, T., Rueda, C., Chung, D., Landau, H., Lahoud, O., Scordo, M., ...> ;Research Square. 2024 Feb 7
• 3 citations
  Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
  Urvi A Shah, Erin Moshier, Andriy Derkach, Yuanhui Huang, Sham Mailankody, Carlyn R Tan, Kylee Maclachlan, Malin Hultcrantz, Neha Korde, Hani Hassoun, Santiago Thibaud...> ;Blood Advances. 2024 Jan 9
• Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study.
  Parikh, R., Francesca Castro, Richa Parikh, Jelyn C Eustaquio, Andriy Derkach, Janine M Joseph, Alexander M Lesokhin, Saad Z Usmani, Urvi A Shah> ;Leukemia. 2024 Feb 1
• Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population.
  Tang, L., Lesokhin, A., Landgren, O., Usmani, S., Moysich, K., Shah, U., Joseph, J., McCann, S., Hillengass, J.> ;Blood Advances. 2024 Feb 13
• 2 citations
  Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
  Francesco Maura, Eileen M Boyle, David Coffey, Kylee Maclachlan, Dylan Gagler, Benjamin Diamond, Hussein Ghamlouch, Patrick Blaney, Bachisio Ziccheddu, Anthony Cirrinc...> ;Nature Cancer. 2023 Dec 1
• 1 citations
  An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma.
  Ross Firestone, Alexander M Lesokhin, Saad Z Usmani> ;Blood Cancer Discovery. 2023 Nov 1
• 9 citations
  Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
  Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H Tomasson, Michael A Damore, Sibo Jiang, Cynthia Basu, A...> ;Nature Medicine. 2023 Oct 1
• Pre-Diagnosis Dietary Patterns and Risk of Multiple Myeloma in the NIH-AARP Diet and Health Study.
  Francesca Castro, Jelyn C Eustaquio, Andriy Derkach, Janine M Joseph, Alexander M Lesokhin, Saad Z Usmani, Urvi A Shah, Parikh, R.> ;Medrxiv. 2023 Sep 23
• 3 citations
  Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.
  David G Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, J Javier Diaz-Mejia, Ping Luo, Yong Zhang, Yuexin Xu, Edus H Warren, Travis Dawson, Brian Lee, Hui Xie, Eric S...> ;Nature Communications. 2023 Sep 2
• 51 citations
  Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
  Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, Nizar J Bahlis, H Miles Prince, Ruben Niesvizky, Paula Rodrίguez-Otero, Joaquin Martinez-Lopez, Guenther Koe...> ;Nature Medicine. 2023 Sep 1
• 13 citations
  Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
  Noopur Raje, Kenneth Anderson, Hermann Einsele, Yvonne Efebera, Francesca Gay, Sarah P Hammond, Alexander M Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krin...> ;Blood Cancer Journal. 2023 Aug 1
• Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
  Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, D...> ;Blood Cancer Journal. 2023 Jul 25
• 7 citations
  Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders.
  Urvi A Shah, Francesca Castro, Matteo Bellone, Alexander M Lesokhin, Parikh, R., Richa Parikh> ;Leukemia. 2023 May 1
• 1 citations
  Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations.
  Kylee H Maclachlan, Tina Bagratuni, Efstathios Kastritis, Bachisio Ziccheddu, Sydney Lu, Venkata Yellapantula, Chris Famulare, Kimon Argyropoulos, Andriy Derkach, Elli...> ;Blood Advances. 2023 Mar 28
• 2 citations
  Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
  Alexander Lesokhin, Richard LeBlanc, Meletios A Dimopoulos, Marcelo Capra, Carmelo Carlo-Stella, Lionel Karlin, Jean-Francois Castilloux, Peter Forsberg, Gurdeep Parma...> ;Cancer Medicine. 2023 May 1
• 1 citations
  Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort ...
  Neha Korde, Elizabet Tavitian, Donna Mastey, Joseph Lengfellner, Gil Hevroni, Andrew Zarski, Meghan Salcedo, Sham Mailankody, Hani Hassoun, Eric L Smith, Malin Hultcra...> ;Eclinicalmedicine. 2023 Mar 1
• 1 citations
  Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma.
  Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, D...> ;Research Square. 2023 Feb 24
• 5 citations
  Extreme body mass index and survival in newly diagnosed multiple myeloma patients.
  Urvi A Shah, Karissa Whiting, Sean Devlin, Rachel Ershler, Bindu Kanapuru, David J Lee, Sabrin Tahri, Thomas Gwise, Even H Rustad, Sham Mailankody, Alexander M Lesokhi...> ;Blood Cancer Journal. 2023 Jan 12
• 8 citations
  Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
  Benjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, Justin Taylor, Eileen Boyle, Juan Arango Ossa, Jacob Jahn, Maurizio Affer, Tulasigeri M Totiger, David Coffey, ...> ;Blood. 2023 May 11
• 1 citations
  Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
  Matthew J Pianko, Timothy Tiutan, Andriy Derkach, Jessica Flynn, Steven P Salvatore, Insara Jaffer-Sathick, Adriana C Rossi, Oscar Lahoud, Malin Hultcrantz, Urvi A Sha...> ;American Journal of Hematology. 2023 Mar 1
• Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
  Kylee H Maclachlan, Alexander M Lesokhin> ;Cancer Cell. 2022 Nov 14
• Join now to see all

Abstracts/Posters

• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients ...
  Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)_CD3 Bispecific Antibody, in P...
  Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy
  Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
  Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
  Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018